Beta Bionics Inc. (BBNX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans
Beta Bionics NASDAQ: BBNX Chief Financial Officer Stephen Feider said the company's first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales coverage and growing confidence in the company's iLet insulin pump platform.
Beta Bionics, Inc. (BBNX) Q1 2026 Earnings Call Transcript
Beta Bionics, Inc. (BBNX) Q1 2026 Earnings Call Transcript
Beta Bionics, Inc. (BBNX) Reports Q1 Loss, Misses Revenue Estimates
Beta Bionics, Inc. (BBNX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.52 per share a year ago.
Beta Bionics, Inc. (BBNX) Soars 10.3%: Is Further Upside Left in the Stock?
Beta Bionics, Inc. (BBNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Beta Bionics, Inc. (BBNX) Reports Q4 Loss, Tops Revenue Estimates
Beta Bionics, Inc. (BBNX) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $1.82 per share a year ago.
Will Beta Bionics, Inc. (BBNX) Report Negative Earnings Next Week? What You Should Know
Beta Bionics, Inc. (BBNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beta Bionics, Inc. (BBNX) Q3 2025 Earnings Call Transcript
Beta Bionics, Inc. (NASDAQ:BBNX ) Q3 2025 Earnings Call October 28, 2025 4:30 PM EDT Company Participants Blake Beber - Head of Investor Relations Sean Saint - President, CEO & Director Stephen Feider - CFO, Treasurer & Secretary Conference Call Participants Michael Kratky - Leerink Partners LLC, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Stephanie Piazzola - BofA Securities, Research Division Michael Polark - Wolfe Research, LLC Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Richard Newitter - Truist Securities, Inc., Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to the Beta Bionics Third Quarter 2025 Earnings Conference Call.
Beta Bionics, Inc. (BBNX) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Beta Bionics, Inc. (BBNX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Beta Bionics, Inc. (BBNX) Q2 2025 Earnings Call Transcript
Beta Bionics, Inc. (NASDAQ:BBNX ) Q2 2025 Earnings Call July 29, 2025 4:30 PM ET Company Participants Blake Beber - Head of Investor Relations Sean T. Saint - President, CEO & Director Stephen H.
BBNX Stock May Gain From Abbott Deal to Advance iLet Integration
Beta Bionics collaborates with Abbott to integrate its iLet system with a dual sensor, aiming to simplify and enhance diabetes care.
Beta Bionics, Inc. (BBNX) Q1 2025 Earnings Call Transcript
Beta Bionics, Inc. (NASDAQ:BBNX ) Q1 2025 Results Conference Call May 6, 2025 4:30 PM ET Company Participants Blake Beber - Head, IR Sean Saint - President and Chief Executive Officer Stephen Feider - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Mike Kratky - Leerink Partners Matthew Blackman - Stifel Travis Steed - Bank of America Jeffrey Cohen - Ladenburg Thalmann Brooks O'Neil - Lake Street Capital Markets Kelly Close - Close Concerns Operator Good afternoon, and welcome to the Beta Bionics First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Beta Bionics: Slowing Down Or Being Conservative?
Beta Bionics' iLet product offers a simplified diabetes treatment, but shares have plunged 60% since the IPO due to a non-inspiring 2025 outlook, indicating potential lost market momentum. Despite strong initial growth and a significant IPO, the company's operating losses and competitive risks warrant a cautious investment stance. The 2025 sales guidance of $80-$85 million implies no sequential growth, raising concerns about market competitiveness and potential margin pressure.
